Patent Expiry

Patent/Exclusivity Expiry: VYXEOS

Drug
VYXEOS

Other upcoming events for COSM

Phase 3 ReadoutPhase 3 Topline: A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patient
Phase 3 ReadoutPhase 3 Topline: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Pat
Phase 3 ReadoutPhase 3 Topline: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology
Patent ExpiryPatent/Exclusivity Expiry: KHAPZORY
Patent ExpiryPatent/Exclusivity Expiry: IMKELDI

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Patent/Exclusivity Expiry: VYXEOS — COSM Patent Expiry | BioSniper